369 related articles for article (PubMed ID: 23549873)
1. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
3. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
4. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
5. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.
Liu NQ; Stingl C; Look MP; Smid M; Braakman RB; De Marchi T; Sieuwerts AM; Span PN; Sweep FC; Linderholm BK; Mangia A; Paradiso A; Dirix LY; Van Laere SJ; Luider TM; Martens JW; Foekens JA; Umar A
J Natl Cancer Inst; 2014 Feb; 106(2):djt376. PubMed ID: 24399849
[TBL] [Abstract][Full Text] [Related]
6. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
7. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
[TBL] [Abstract][Full Text] [Related]
8. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
9. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
10. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
12. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
13. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
14. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
16. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
17. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
19. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
